ResMed Inc. (RMD)

Sleep and respiratory devices with care software. Read October 19, 2026 from the annual report for the period ending June 30, 2026, filed August 13, 2026. Ranked 47 of the 95 Healthcare companies read so far, by the share within reach now.

ResMed states approximately 11,370 employees at June 30, 2026, 4,590 in cost of sales activities such as manufacturing and warehousing, 2,300 in research and development and 4,480 in sales, marketing and administration, so the device business takes the function counts (a) and the care software its revenue share by description (c).

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 40% at the end of 2028, 42% at the end of 2030. By the patterns, the work is about 42% desk work, 16% people work and 41% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 53% of the working time stays with people (conversation, in-person and hands-on work), 37% becomes checking a model's work and 7% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

11,370 employees as of June 30, 2026 (stated). The filing counts 3,490 (31%) in the Americas, 3,560 (31%) in Asia, 1,650 (15%) in Australia and 2,670 (23%) in Europe; the U.S. alone is not stated.

The filing: “As of June 30, 2026, we had approximately 11,370 employees, of which approximately 4,590 were employed in cost of sales activities including areas such as warehousing and manufacturing, 2,300 in research and development and 4,480 in sales, marketing and administration.”

The workforce as industry patterns

What the filing says about the workforce: By function: 4,590 in cost of sales activities (warehousing and manufacturing), 2,300 in research and development, 4,480 in sales, marketing and administration; by region 31% Americas, 31% Asia, 15% Australia, 23% Europe; global turnover about 13%.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Medical Equipment and Supplies Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Abbott Laboratories (ABT, 115,000 employees)18% now, 35% by 2028
• Becton, Dickinson and Company (BDX, 72,000 employees)19% now, 36% by 2028
• Boston Scientific Corporation (BSX, 59,000 employees)19% now, 42% by 2028
• Stryker Corporation (SYK, 56,000 employees)19% now, 39% by 2028
• Baxter International Inc. (BAX, 37,500 employees)19% now, 37% by 2028
• Align Technology, Inc. (ALGN, 20,290 employees)19% now, 36% by 2028
• Solventum Corporation (SOLV, 20,000 employees)20% now, 43% by 2028
• STERIS plc (STE, 17,937 employees)22% now, 39% by 2028

What the filing says about AI

40 sentences in the filing name AI. The filing presents AI-powered digital health solutions, cloud-connected devices and intelligent software as its product design, with AI and machine learning algorithms to enhance therapy performance and an AI-driven digital platform tied to its Residential Care Software.

• “Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective.”
• “We aim to continue differentiating our products by integrating artificial‑intelligence and machine‑learning, or AI and ML, algorithms to further enhance therapy performance and user experience.”
• “Our leading Residential Care Software solutions are a key enabler of our Sleep and Breathing Health business, driving revenue synergies, contributing to demand generation and providing cohesion and interoperability for our AI-driven digital platform.”
• “Smart Comfort, launched in early 2026 to select new myAir users, is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings to help patients with OSA start and stay on CPAP therapy.”
• “Core software functionality covers invoicing, EHR and staff rostering, augmented by integrated solutions such as AI-based workflow automation, e-learning for nurses, and revenue cycle management.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20226median 0
• Fiscal 20239median 1
• Fiscal 202411median 4
• Fiscal 202531median 10
• Fiscal 202640

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The U.S. share is not stated; the Americas hold 31%.
• The software business has no count of its own; its share is by revenue (c).

Source: the company's annual report on EDGAR, accession 0000943819-26-000047, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.